Gangadaran Sittu Govindasamy Dinakaran
Medical Oncology, Govt. Royapettah Hospital, Chennai, India.
Oncol Rev. 2017 Jun 14;11(2):339. doi: 10.4081/oncol.2017.339.
Renal cancer accounts for 2.4% of all cancers. Localised disease accounts for the majority of renal cancers (70-75%), however 20-25% of these ultimately develop distant metastasis. The median overall survival of un treated metastatic disease is 5 months with 1-year survival of only 29%. The management of metastatic renal cell cancers traditionally relied on systemic immunotherapy with attendant high morbidity but after the year 2005 the use of effective targeted therapy with tolerable side effect profile has improved the survival from 10.2 months in the cytokine era to 17.7 months. This article reviews the past, present and future options in the management of metastatic renal cancer.
肾癌占所有癌症的2.4%。局限性疾病占大多数肾癌病例（70-75%），然而其中20-25%最终会发生远处转移。未经治疗的转移性疾病的中位总生存期为5个月，1年生存率仅为29%。转移性肾细胞癌的治疗传统上依赖全身免疫治疗，随之而来的是高发病率，但在2005年之后，使用具有可耐受副作用的有效靶向治疗已将生存期从细胞因子时代的10.2个月提高到了17.7个月。本文综述了转移性肾癌治疗的过去、现在和未来选择。
